Genomic landscape of metastatic breast cancers in young adults: A liquid biopsy analysis of women aged 20-40 years

Researchers used data from patients enrolled in the STING molecular profile platform to assess the genomic landscape of young adult patients with metastatic breast cancer. Of the data evaluated, 79% of patients presented with actionable ESMO Scale of Clinical Actionability genomic alterations. This supports the role of molecular profiling in this patient population, although a larger cohort is needed for study validation.